| DB ID | MyCo_1727 |
| Title | Potential value of serum Aspergillus IgG antibody detection in the diagnosis of invasive and chronic pulmonary aspergillosis in non-agranulocytic patients |
| Year | 2020 |
| PMID | 32293386 |
| Fungal Diseases involved | Chronic pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study was approved by the ethics committee of Tianjin Chest Hospital (protocol number: 2018KY-009-01). |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Serum IgG |
| Biomarker Full Name | Serum Immunoglobulin G |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | China |
| Cohort | Fifty-eight pulmonary aspergillosis cases in nonagranulocytic patients admitted to Tianjin Chest Hospital from July 2017 to July 2018 were enrolled. The diagnostic criteria referred to the consensus of experts in the diagnosis and treatment of pulmonary mycosis and the criteria of the European Organization for Research and Treatment of Cancer (EORTC). The exclusion criteria were as follows: (1) agranulocytic patients, (2) patients with other lung diseases, (3) patients with possible pulmonary aspergillosis, (4) patients with allergic bronchopulmonary aspergillosis, and (5) patients who were positive for human immunodeficiency virus (HIV). |
| Cohort No. | 58 Patient + 50 Control |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Pulmonary aspergillosis is a type of lung disease caused by Aspergillus infection or the inhalation of Aspergillus antigen. Pulmonary aspergillosis is uncommon in nonagranulocytic patients, and only a small amount of data are available. Nevertheless, in recent years, the incidence of pulmonary aspergillosis in non-granulocytic patients has increased with ageing; the increase in chronic diseases; the use of broad-spectrum antibiotics, hormones, and immunosuppressive drugs; and invasive operations. Moreover, the clinical manifestations of these patients lack specificity, and the diagnosis is usually difficult, which leads to treatment delay and affects the prognosis. According to the clinical characteristics, pulmonary Aspergillosis can be divided into allergic bronchopulmonary Aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), invasive pulmonary aspergillosis (IPA), and subacute invasive aspergillosis (SAIA). Among them, CPA usually occurs in immunocompetent individuals with underlying respiratory disorders, and the prevalence of CPA worldwide is approximately 3 million. Unfortunately, respiratory physicians may not detect CPA until the disease progresses to an advanced stage owing to the lack of specific clinical manifestations. More seriously, without timely diagnosis and long-term antifungal treatment, the 5-year mortality rate of patients with CPA reaches 80% . Furthermore, invasive pulmonary aspergillosis (IPA) has become a common type of severe pneumonia with the highest mortality, and one of the important reasons the is difficulty in diagnosis. In addition, patients with agranulocytosis are predominant among those with IPA, and relevant international guidelines for diagnosis and treatment also focus on them. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA kit (Dynamiker Biotechnology Co., Ltd. Tianjin, China) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |
